

## Results of Annual General Meeting

**Perth, Australia – 6 November 2025:** Orthocell Limited (ASX: OCC, “Orthocell” or “the Company”) advises that its Annual General Meeting of Shareholders was held today at 10.00 am AWST.

The resolutions were voted in accordance with the Notice of Annual General Meeting and Supplementary Notice of Annual General Meeting previously advised to the Australian Securities Exchange, with all resolutions being carried on a poll.

Resolution 9 (Amendment of the Constitution) was carried by a sufficient majority as a special resolution.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached.

**Release authorised by:**

**Paul Anderson**

**Orthocell Ltd CEO and MD**

**For more information, please contact:**

**General enquiries**

**Paul Anderson**

Orthocell Limited  
CEO and MD

P: +61 8 9360 2888

E: [paul.anderson@orthocell.com](mailto:paul.anderson@orthocell.com)

**Media enquiries**

**Haley Chartres**

**H<sup>^</sup>CK Director**

P: +61 423 139 163

E: [haley@hck.digital](mailto:haley@hck.digital)

**Investor enquiries**

**Shaun Duffy**

**VECTOR Advisors**

P: +61 404 094 384

E: [sduffy@vectoradvisors.au](mailto:sduffy@vectoradvisors.au)

**About Orthocell Limited**

**ACN 118 897 135**

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed 14 US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand and Canada. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

**For more information on Orthocell, please visit [www.orthocell.com](http://www.orthocell.com) or follow us on Twitter @OrthocellLtd and LinkedIn [www.linkedin.com/company/orthocell-ltd](http://www.linkedin.com/company/orthocell-ltd)**

For personal use only

# Disclosure of Proxy Votes

Orthocell Limited  
Annual General Meeting  
Thursday, 06 November 2025



**AUTOMIC**  
Automic  
GPO Box 5193, Sydney, NSW 2001  
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)  
F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)  
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Non Binding Resolution to adopt Remuneration Report	P	70,251,129	51,268,093 72.98%	14,840,951 21.13%	824,706	4,142,085 5.90%	58,340,756 79.29%	15,241,309 20.71%	877,056	-
2 Re-election of Mr Michael McNulty as a Director	P	76,452,132	68,191,691 89.20%	3,859,436 5.05%	3,205,666	4,401,005 5.76%	75,978,615 95.17%	3,859,436 4.83%	3,299,626	Carried
3 Approval of Employee Awards Plan	P	62,093,390	43,685,182 70.35%	14,279,922 23.00%	1,210,069	4,128,286 6.65%	50,594,607 77.22%	14,921,329 22.78%	1,170,809	Carried
4 Increase in non-executive Directors' cash fees	P	71,742,107	52,162,078 72.71%	14,948,849 20.84%	684,628	4,631,180 6.46%	59,667,819 79.49%	15,398,974 20.51%	743,228	Carried
5 Issue of Fee Shares to Mr John Van Der Wielen or his nominee(s)	P	71,811,439	53,220,950 74.11%	14,458,501 20.13%	615,296	4,131,988 5.75%	60,333,874 80.28%	14,816,891 19.72%	659,256	Carried
6 Issue of Fee Shares to Dr Ravi Thadhani or his nominee(s)	P	71,811,439	52,818,467 73.55%	14,860,984 20.69%	615,296	4,131,988 5.75%	59,881,391 79.73%	15,219,374 20.27%	709,256	Carried
7 Issue of Fee Shares to Professor Fiona Wood AM or her nominee(s)	P	71,818,439	52,767,019 73.47%	14,922,432 20.78%	608,296	4,128,988 5.75%	59,876,943 79.67%	15,280,822 20.33%	652,256	Carried
8 Issue of Fee Shares to Mr Michael McNulty or his nominee(s)	P	71,189,487	53,532,779 75.20%	13,524,720 19.00%	1,237,248	4,131,988 5.80%	60,645,703 81.37%	13,883,110 18.63%	1,281,208	Carried



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Amendment of the Constitution	P	74,720,738	61,428,560 82.21%	8,634,115 11.56%	4,937,060	4,658,063 6.23%	69,113,794 88.49%	8,992,863 11.51%	5,031,020	Carried
10 Issue of Short-Term Performance Rights to Mr Paul Anderson or his nominee(s)	P	69,182,748	52,673,773 76.14%	12,390,695 17.91%	884,267	4,118,280 5.95%	59,782,906 82.37%	12,796,945 17.63%	886,617	Carried
11 Approval of potential termination benefits to Mr Paul Anderson in relation to Short-Term Performance Rights	P	68,607,087	52,415,457 76.40%	12,043,350 17.55%	1,459,928	4,148,280 6.05%	59,240,840 82.33%	12,713,350 17.67%	1,512,278	Carried

